Chronic hepatitis C and normal ALT: considerations for treatment

Area of Science:

• Hepatology
• Viral Hepatitis Research
• Clinical Medicine

Background:

• Chronic hepatitis C treatment has evolved significantly over 14 years.
• Initially, patients with persistently normal alanine aminotransferase (ALT) levels were not prioritized for treatment.
• Advancements in treatment efficacy have led to increased consideration for all patient groups.

Discussion:

• Jacobson and colleagues' research indicates comparable treatment responses between normal and elevated ALT groups.
• The combination therapy of interferon and ribavirin showed similar efficacy in both patient cohorts.
• This challenges the traditional view of ALT levels as a primary determinant for initiating therapy.

Key Insights:

• Alanine aminotransferase (ALT) levels are an inadequate marker for assessing chronic hepatitis C disease severity.
• ALT levels should not be the sole or primary factor in deciding on treatment initiation for chronic hepatitis C.
• Patients with normal ALT levels can achieve similar therapeutic benefits from interferon and ribavirin combination therapy.

Outlook:

• Future treatment guidelines may de-emphasize ALT levels in chronic hepatitis C management.
• Further research could explore optimal treatment strategies irrespective of baseline ALT.
• This finding supports broader application of effective hepatitis C therapies.